logo

Indian News

Share

pharma-daily-052218.jpg Today's Daily Dose brings you news about FDA approval of AstraZeneca's hyperkalemia drug; Dova's platelet booster Doptelet getting regulatory nod; the fifth indication for Amgen's Prolia securing thumbs-up; Sesen's encouraging three-month data from the VISTA trial and investors' concern and Nabriva's LEAP 2 study results.

ebio-may21.jpg NuCana plc (NCNA) has appointed Cyrille Leperlier to its Board as an independent non-executive Director.

india-crypto-052118.jpg A top official of India's Economic Affairs ministry has announced that a high-level Committee would submit its report on cyrptocurrencies to the government soon. In December, the government of India constituted a three member committee headed by Economic Affairs Secretary S C Garg to study the impact of cryptocurrencies and to make recommendations to regulate them. Other members of the panel inclu

avenuetherapeutics-031518.jpg Investors of Avenue Therapeutics Inc. (ATXI) have a reason to smile today, as the shares are up over 30% in pre-market trading.

pharma-daily-051718.jpg Another week has gone by, and it was raining FDA approvals. Now, here are some of the pharma/biotech stocks and upcoming events to keep an ear out for in the coming week.

infosys-blockchain-051818.jpg Indian IT giant Infosys has partnered with seven Indian banks for a blockchain-based trade finance network. Infosys Finacle, part of EdgeVerve Systems, a product unit of Infosys, announced the development of India Trade Connect or ITC in partnership with the banking consortium. ITC's goal is to digitize trade finance workflows within a distributed, trusted, and shared network.

rbi-suprem-court-0518180.jpg Indian Supreme Court has refused to stay the central bank's ban on the country's commercial banks from providing services to investors in digital currencies. In a writ petition challenging the ban, a group of lawyers pleaded with the apex court to allow banks to continue serving cryptocurrency clients as they had prior to the RBI ban. A three-judge bench headed by Supreme Court Chief Justice Deepa

pharma-gainers-051718.jpg Eiger Pharmaceutical Inc. (EIGR) has expanded its licensing agreement with Merck to include rights to develop experimental drug Lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), a rare and fatal genetic condition characterized by accelerated aging in children.

Follow RTT